Table 4.

Sensitivity analysis on subclinical hyperthyroidism and incident diabetes at last available follow-up

Sensitivity analysis	No. of participants		No. of included studies	OR (95% CI)
	Euthyroid	Shyper
1) Excluding participants with thyroid medication *	19765	470	9	0.91 (0.65–1.26)
2) Excluding participants with thyroid-altering medication **	14080	230	5	0.83 (0.49–1.40)
3) Limiting analyses to participants with repeated TFT at FU	13979	567	2	0.97 (0.36–2.60)
4) Using additional data to define diabetes †	44928	1584	12	1.00 (0.81–1.22)
5) Excluding participants without or with abnormal FT3 measurement	15397	467	6	0.94 (0.66–1.34)
6) Limiting analyses to studies with <20% missing data at follow-up	13387	257	2	1.01 (0.63–1.62)
7) Limiting analyses to high-quality studies ‡	31659	1088	12	1.03 (0.82–1.30)

Shyper: subclinical hyperthyroidism; OR: odds ratio; CI: confidence interval; TFT: thyroid function test; FU: follow-up

^*Thyroid medication was defined as levothyroxine or anti-thyroid medication use

^**Thyroid-altering medication was defined as levothyroxine, anti-thyroid medication, lithium, or amiodarone use

^†If available, self-reported diabetes and linkage to medical records was used to define diabetes

^‡All studies were classified as good quality according to the Newcastle-Ottawa quality assessment scale for cohort studies